Steven D. Averbuch, M.D.

Steven D. Averbuch, M.D.

Dr. Averbuch is currently Vice President, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb Company based in Lawrenceville, NJ, USA.  In this role, Steve serves as the Executive Sponsor of the Translational R&D teams across the Full Development and Life Cycle Management pipeline.

Karen Anderson, M.D., Ph.D.

Karen Anderson, M.D., Ph.D.

Dr. Anderson obtained her MD and Ph.D. at Duke University, and her clinical hematology/oncology training at the Dana Farber Cancer Institute in Boston, where she was a faculty member until 2011. She is currently a translational research scientist and Associate Professor at the Biodesign Institute at Arizona State University and the Mayo Clinic Arizona. She has extensive experience in the clinical translation of novel experimental diagnostics and therapeutics for cancer.

Jannik N. Andersen, Ph.D.

Jannik N. Andersen, Ph.D.

Jannik Andersen, Ph.D., has extensive expertise in basic and translational cancer research, oncogenic signaling and targeted oncology therapeutics. Prior to joining MD Anderson, he was the associate director of drug discovery at the Belfer Institute of Applied Cancer Science at Dana-Farber Cancer Institute, where he served as the science alliance manager for the corporate partnership with Merck & Co., Inc.

Pages

Subscribe to National Biomarker Development Alliance (NBDA) RSS